Dow Dips 350 Points; S&P 500 Down Over 1%
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 300 points on Friday.
The Dow traded down 1.07% to 32,798.91 while the NASDAQ fell 1.90% to 11,370.53. The S&P 500 also fell, dropping, 1.23% to 3,963.05
US Stocks Open Lower; Dow Drops 1%
U.S. stocks traded lower this morning, with the Dow Jones dropping over 150 points on Friday.
Following the market opening Friday, the Dow traded down 1.05% to 32,807.33 while the NASDAQ fell 1.52% to 11,413.98. The S&P 500 also fell, dropping, 1.22% to 3,963.44.
Why Sellas Life Sciences Shares Are Nosediving
Sellas Life Sciences Group Inc (NASDAQ: SLS) shares are trading lower by 52.57% to $1.75 Friday morning after the company announced pricing of a $20 million underwritten public offering.
What Else?
Sellas Life Sciences Group Announces John T. Burns, The Company’s Senior Vice President, Finance And Chief Accounting Officer, As The Company’s Chief Financial Officer And Principal Financial Officer
On February 2, 2023, the Board of Directors (the “BOD”) of the Company appointed John T. Burns, the Company’s Senior Vice President, Finance and Chief Accounting Officer, as the Company’s Chief
SELLAS Life Sciences Highlights Data From Early Study In Blood Cancer Patients
SELLAS Life Sciences Group Inc (NASDAQ:SLS) announced results from its ongoing dose-escalating Phase 1 study of GFH009 in patients with relapsed…
SELLAS Life Sciences’ CDK9 Inhibitor GFH009 Demonstrates Tumor Growth Inhibition In Small Cell Lung Cancer Murine Model
GFH009 exhibits robust activity against small cell lung cancer xenografts, both as monotherapy and in combination with PARP inhibitor olaparib
Results support designating small cell lung cancer as first
Dow Surges 150 Points; Crude Oil Falls Sharply
U.S. stocks traded mostly higher toward the end of trading, with the Dow Jones gaining around 150 points on Monday.
SELLAS Life Sciences Shares Tumble As Acute Myeloid Leukemia Trial Will Longer Than Anticipated
SELLAS Life Sciences Group Inc (NASDAQ:SLS) announced updates relating to its ongoing Phase 3 REGAL study for galinpepimut-S (GPS) in acute…